The effects of tumor mass, tumor age, and external beam radiation on tumor-specific antibody uptake

Jy, Wong; Le, Williams; Hill, L. Robert; Rj, Paxton; Bg, Beatty; Je, Shively; Jd, Beatty

doi:10.1016/0360-3016(89)90490-2

Cited by 21 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patient stratification is possible by using PET-tracers in a theranostic approach revealing treatment personalization [11][12][13]. In addition, RT has the potential to destroy some of the drug-delivery barriers leading to positive effects of irradiation on radiolabeled drug uptake [2,[14][15][16][17][18][19][20][21]. Thus, the scheduling of combined approaches may impact it's efficacy.…”

Section: Discussionmentioning

confidence: 99%

“…In contrast, environmental factors like perfusion, permeability, necrosis, tissue density and interstitial pressure determine tracer uptake [11,[38][39][40] and are influenced by fractionated irradiation [24,41]. An increased drug uptake after irradiation is reported in different preclinical experiments [2,[14][15][16][17][18][19][20] and in a clinical setting [21]. However, the effects, which might improve radiolabled drug uptake during fractionated radiotherapy, are dependent on diverse aspects and will differ if other tumor entities are taken into account.…”

Section: Combination Of Molecular and External Radiotherapymentioning

confidence: 99%

See 1 more Smart Citation

Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial

Dietrich

Andreeff

Koi

et al. 2021

Radiotherapy and Oncology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Combination Of Molecular and External Radiotherapymentioning

confidence: 99%

Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial

Dietrich

Andreeff

Koi

et al. 2021

Radiotherapy and Oncology

View full text Add to dashboard Cite

“…Pre-clinical investigations on CIERT have been published for more than 25 years 53,54 and are summarized in Table 2. Comparison of different data sets is limited because they differ in almost all aspects: model systems, tumour entities, target antigens, radionuclides, delivered activities and doses, treatment schedules and end points.…”

Section: Pre-clinical Results: Promises and Challenges Of Combinationmentioning

confidence: 99%

“…Many early studies showed enhanced tumour uptake of radiolabelled antibodies after EBRT. 53,54,73,74 Suggested reasons were an increase of the vascular permeability after EBRT 73 and the shrinkage of tumour mass 54,75 with RIT being more effective on smaller target volumes. 66,75 The effect was dose dependent and did not lead to a higher uptake in normal tissues if X-rays were used.…”

Section: 65mentioning

confidence: 99%

Improving external beam radiotherapy by combination with internal irradiation

Dietrich¹,

Koi²,

Zöphel³

et al. 2015

BJR

View full text Add to dashboard Cite

The efficacy of external beam radiotherapy (EBRT) is dose dependent, but the dose that can be applied to solid tumour lesions is limited by the sensitivity of the surrounding tissue. The combination of EBRT with systemically applied radioimmunotherapy (RIT) is a promising approach to increase efficacy of radiotherapy. Toxicities of both treatment modalities of this combination of internal and external radiotherapy (CIERT) are not additive, as different organs at risk are in target. However, advantages of both single treatments are combined, for example, precise high dose delivery to the bulk tumour via standard EBRT, which can be increased by addition of RIT, and potential targeting of micrometastases by RIT. Eventually, theragnostic radionuclide pairs can be used to predict uptake of the radiotherapeutic drug prior to and during therapy and find individual patients who may benefit from this treatment. This review aims to highlight the outcome of pre-clinical studies on CIERT and resultant questions for translation into the clinic. Few clinical data are available until now and reasons as well as challenges for clinical implementation are discussed.

show abstract

“…Several studies have noted enhanced accumulation of targeted radionuclides as a result of increased vessel permeability following EBRT [5] , [28] , [29] , [30] . In this study, vessel permeability was evaluated by DCE-MRI after EBRT to elucidate the optimal time for 131 I-mIBG treatment.…”

Section: Discussionmentioning

confidence: 99%

Improved outcome of 131 I-mIBG treatment through combination with external beam radiotherapy in the SK-N-SH mouse model of neuroblastoma

Corroyer‐Dulmont

Falzone

Kersemans

et al. 2017

Radiotherapy and Oncology

View full text Add to dashboard Cite

PurposeTo assess the efficacy of different schedules for combining external beam radiotherapy (EBRT) with molecular radiotherapy (MRT) using 131I-mIBG in the management of neuroblastoma.Materials and methodsBALB/c nu/nu mice bearing SK-N-SH neuroblastoma xenografts were assigned to five treatment groups: 131I-mIBG 24 h after EBRT, EBRT 6 days after 131I-mIBG, EBRT alone, 131I-mIBG alone and control (untreated). A total of 56 mice were assigned to 3 studies. Study 1: Vessel permeability was evaluated using dynamic contrast-enhanced (DCE)-MRI (n = 3). Study 2: Tumour uptake of 131I-mIBG in excised lesions was evaluated by γ-counting and autoradiography (n = 28). Study 3: Tumour volume was assessed by longitudinal MR imaging and survival was analysed (n = 25). Tumour dosimetry was performed using Monte Carlo simulations of absorbed fractions with the radiation transport code PENELOPE.ResultsGiven alone, both 131I-mIBG and EBRT resulted in a seven-day delay in tumour regrowth. Following EBRT, vessel permeability was evaluated by DCE-MRI and showed an increase at 24 h post irradiation that correlated with an increase in 131I-mIBG tumour uptake, absorbed dose and overall survival in the case of combined treatment. Similarly, EBRT administered seven days after MRT to coincide with tumour regrowth, significantly decreased the tumour volume and increased overall survival.ConclusionsThis study demonstrates that combining EBRT and MRT has an enhanced therapeutic effect and emphasizes the importance of treatment scheduling according to pathophysiological criteria such as tumour vessel permeability and tumour growth kinetics.

show abstract

The effects of tumor mass, tumor age, and external beam radiation on tumor-specific antibody uptake

Cited by 21 publications

References 9 publications

Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial

Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial

Improving external beam radiotherapy by combination with internal irradiation

Improved outcome of 131 I-mIBG treatment through combination with external beam radiotherapy in the SK-N-SH mouse model of neuroblastoma

Contact Info

Product

Resources

About